Sector: Healthcare
ID_KLBF
Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.
Shares: connector/market_inputs
Monetary columns are in B IDR, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.
| Date | Period | Status | RevenueB IDR | Operating profitB IDR | D&AB IDR | EBITDAB IDR | Net profitB IDR | Operating CFB IDR | Capex + M&AB IDR | AssetsB IDR | EquityB IDR | ROE (annualized) | Net debtB IDR | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Q1 2026 (3M) | OK | 9.7 y/y 9.4% | 1.4 y/y -5.4% | 0.2 y/y 11.8% | 1.6 y/y -3.5% | 1.0 y/y -4.4% | 0.3 | -155.3 | 32.0 y/y 4.6% | 25.7 y/y 1.5% | 16.3% | -4.1 | Report (PDF) |
| 2025-12-31 | Q4 2025 (3M) | OK | 9.3 y/y 11.3% | 1.3 y/y 18.0% | 0.2 y/y 13.5% | 1.5 y/y 17.4% | 1.0 y/y 19.9% | 1.1 | -220.1 | 30.7 y/y 4.3% | 24.7 y/y 0.6% | 14.8% | -4.0 | Report (PDF) |
| 2025-09-30 | Q3 2025 (3M) | OK | 8.9 y/y 12.6% | 0.9 y/y 19.2% | 0.2 y/y 5.6% | 1.1 y/y 16.3% | 0.7 y/y 14.5% | 0.9 | -217.1 | 30.1 y/y 4.7% | 24.8 y/y 3.7% | 3.6% | -3.5 | Link |
| 2025-06-30 | Q2 2025 (3M) | OK | 8.2 y/y 3.4% | 1.1 y/y -1.1% | 0.2 y/y 7.9% | 1.3 y/y 0.3% | 0.9 y/y 6.0% | 1.0 | -145.5 | 29.5 y/y 3.3% | 24.2 y/y 2.8% | 14.5% | -3.0 | Link |
| 2025-03-31 | Q1 2025 (3M) | OK | 8.8 y/y 5.8% | 1.4 y/y 12.8% | 0.2 y/y 0.9% | 1.6 y/y 11.3% | 1.1 y/y 12.4% | 0.3 | -143.1 | 30.6 y/y 5.6% | 25.4 y/y 5.2% | 17.2% | -4.0 | Report (PDF) |
| 2024-12-31 | Q4 2024 (3M) | OK | 8.4 y/y — | 1.1 y/y — | 0.2 y/y — | 1.2 y/y — | 0.9 y/y — | 1.3 | -235.4 | 29.4 y/y — | 24.6 y/y — | 13.4% | -4.2 | Report (PDF) |
| 2024-09-30 | Q3 2024 (3M) | OK | 7.9 y/y 7.2% | 0.7 y/y 3.0% | 0.2 y/y 6.2% | 0.9 y/y 3.7% | 0.6 y/y 7.0% | 1.2 | -262.7 | 28.8 y/y 5.8% | 23.9 y/y 6.9% | 3.2% | -3.4 | Link |
| 2024-06-30 | Q2 2024 (3M) | OK | 8.0 y/y 9.0% | 1.1 y/y 23.1% | 0.2 y/y 11.4% | 1.3 y/y 21.1% | 0.8 y/y 25.9% | 1.2 | -197.4 | 28.6 y/y 4.2% | 23.5 y/y 8.1% | 14.2% | -2.7 | Link |
| 2024-03-31 | Q1 2024 (3M) | OK | 8.4 y/y — | 1.3 y/y — | 0.2 y/y — | 1.4 y/y — | 1.0 y/y — | 1.2 | -212.4 | 29.0 y/y — | 24.1 y/y — | 16.2% | -3.4 | Report (PDF) |
| 2023-12-31 | Q4 2023 (3M) | OK | 7.9 y/y — | 1.0 y/y — | 0.2 y/y — | 1.1 y/y — | 0.7 y/y — | 0.5 | -34.9 | 27.1 y/y — | 23.1 y/y — | 12.3% | -2.8 | Link |
| 2023-09-30 | Q3 2023 (3M) | OK | 7.4 y/y — | 0.7 y/y — | 0.2 y/y — | 0.9 y/y — | 0.5 y/y — | 0.6 | -89.9 | 27.2 y/y — | 22.4 y/y — | 3.2% | -1.9 | Link |
| 2023-06-30 | Q2 2023 (3M) | OK | 7.3 y/y — | 0.9 y/y — | 0.2 y/y — | 1.0 y/y — | 0.7 y/y — | 0.3 | -165.0 | 27.4 y/y — | 21.8 y/y — | — | -1.1 | Link |
Quarterly values ($ mln)
Year-over-year change
FCF ($ mln)
Net debt / cash ($ mln)
Value the company creates per year, as a % of market cap
Value created per year: -2.8%
| 1. EBITDA growth (latest quarter YoY, annualised) [EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-03-31 vs 2025-03-31) = (1 554 486 − 1 610 566) × 3.44 | -192 816 |
| 2. Current EV/EBITDA (LTM) (Market cap + Net debt) ÷ EBITDA (LTM) = (32 580 000 + -4 087 001) ÷ 5 344 737 | 5.3x |
| 3. Target multiple (Current EV/EBITDA + 9) ÷ 2 = (5.3 + 9) ÷ 2 | 7.2x |
| 4. Cash flow (balance method, LTM) Net-debt reduction + dividends + buybacks − equity issuance = 484 718 + 0 + 0 − 0 | 484 718 |
| 5. Value created per year (EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap = (-192 816 × 7.2 + 484 718) ÷ 32 580 000 | -2.8% |
Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.
Caveats:
| Date | Per share | Details | Status | Source |
|---|---|---|---|---|
| 2026-06-04 | 20 IDR | Ex-dividend: 20 IDR per share | Paid | Yahoo Finance (ex-div) |
| 2025-06-04 | 36 IDR | Ex-dividend: 36 IDR per share | Paid | Yahoo Finance (ex-div) |
| 2024-05-29 | 31 IDR | Ex-dividend: 31 IDR per share | Paid | Yahoo Finance (ex-div) |
| 2023-05-12 | 38 IDR | Ex-dividend: 38 IDR per share | Paid | Yahoo Finance (ex-div) |
| 2022-05-31 | 35 IDR | Ex-dividend: 35 IDR per share | Paid | Yahoo Finance (ex-div) |
KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).
Investor reporting (IR): https://www.kalbe.co.id/investor-relations
Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)
Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Kalbe Farma (KLBF) — from primary filings.
Kalbe Farma develops, manufactures, and sells pharmaceutical products, including prescription drugs, consumer health items, and nutritional products, and also operates distribution and logistics services in Indonesia.